The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Glofitamab plus R-CHOP in patients with high-risk LBCL: a Phase II trial
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a Phase II trial (NCT04980222) investigating glofitamab plus R-CHOP in patients with previously untreated large B-cell lymphoma (LBCL) who are defined as high-risk by the levels of circulating tumor DNA (ctDNA). The findings reveal a manageable safety profile, with a low incidence and severity of cytokine release syndrome (CRS), and a complete metabolic response (CMR) rate of 85%. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Advisory board: AstraZeneca, Genentech, Abbvie, Ipsen, ADC Therapeutics, Seagen
Consultancy: Genmab, Roche, Genentech, Abbvie, Evolveimmune
Honoraria: Genmab, Genentech, Abbvie
Travel Expenses: Genmab, Abbvie
Research Funding: Genmab, Roche, Genentech, Abbvie, Innate Pharma
